Chronic Obstructive Pulmonary Disease (COPD) Market

Rise in prevalence of CPOD across the globe to boost market growth

Chronic obstructive pulmonary disease (COPD) is a major health concern affecting a large number of people across the globe. The disease burden is rising, thereby increasing the need for COPD management. Tobacco smoking could lead to COPD. The number of adults addicted to smoking has been increasing across the globe. Other risk factors include occupation and indoor air pollution. According to the World Health Organization (WHO), the primary cause of COPD is exposure to tobacco smoke. 

According to the organization, chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, accounting for 3.23 million deaths in 2022. Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC).

According to a report by the Initiative for Chronic Obstructive Lung Disease (GOLD) published in 2022, the prevalence and burden of COPD are projected to increase in the near future due to continued exposure to COPD risk factors, rise in the incidence of interstitial lung diseases, and aging population across the world. 

This is anticipated to augment the Chronic Obstructive Pulmonary Disease Treatment (COPD) market in the near future. The graph that follows illustrates the crude and weighted prevalence of COPD, overall and in men and women. Age-specific prevalence of COPD in men and women. Bars represent the prevalence and error bars the 95% clinical informatics.

The Global Chronic Obstructive Pulmonary Disease (COPD) Market Industry is experiencing growth due to the increasing prevalence of COPD worldwide. According to health statistics, millions of individuals are diagnosed with COPD each year, with the World Health Organization estimating that COPD will become the third leading cause of death globally by 2030. This alarming trend is prompting healthcare systems to allocate more resources towards COPD management and treatment, thereby expanding the market. The anticipated market value of 22.1 USD Billion in 2024 reflects this growing concern, as governments and organizations strive to improve patient outcomes and reduce the burden of this chronic disease.

By Region, the study segments the market into North America, Europe, Asia-Pacific and Rest of the World. North America Chronic Obstructive Pulmonary Disease Treatment (COPD) held the largest market share in 2021. This is attributed to the increased investment in R&D activities to develop innovative drugs for treating diseases. 

Also, the rise in incidence and prevalence of chronic respiratory diseases, technological advancement, growing healthcare sectors, and massive presence of leading market players are some of the major factors that boost the COPD Market in the region.

Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT (COPD) MARKET SHARE BY REGION 2021 (%)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Chronic Obstructive Pulmonary Disease Treatment (COPD) market accounts for the second-largest market share due to the well-developed healthcare infrastructure and an increase in the incidence of chronic obstructive pulmonary diseases are propelling the COPD treatment market in the region. Further, the Germany Chronic Obstructive Pulmonary Disease Treatment (COPD) market held the largest market share, and the UK Chronic Obstructive Pulmonary Disease Treatment (COPD) market was the fastest growing market in the European region.

The Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment (COPD) market is expected to grow with a significant share. This is due to the untapped chronic obstructive pulmonary disease treatment market compared to developed regions. Therefore, Asia Pacific offers significant opportunities to market players. High prevalence of chronic obstructive pulmonary disease, increase in geriatric population, surge in patient population, and growth of the health care industry are propelling the chronic obstructive pulmonary disease treatment market in the region.

Moreover, China Chronic Obstructive Pulmonary Disease Treatment (COPD) market held the largest market share, and the India Chronic Obstructive Pulmonary Disease Treatment (COPD) market was the fastest growing market in the Asia-Pacific region. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2024–2032.

Major market players are spending a lot of money on R&D to increase their product lines, which will help the Chronic Obstructive Pulmonary Disease Treatment (COPD) market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Chronic Obstructive Pulmonary Disease (COPD) industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the Chronic Obstructive Pulmonary Disease Treatment (COPD) industry to benefit clients and expand the Chronic Obstructive Pulmonary Disease Treatment (COPD) market sector is to manufacture locally to reduce operating costs. In recent years, Chronic Obstructive Pulmonary Disease (COPD) has provided medicine with some of the most significant benefits.

Alembic Pharmaceuticals Ltd. is a leading pharmaceutical company committed to develop, manufacture and market pharmaceutical products, pharmaceutical substances, and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs. In May 2022, Alembic Pharmaceuticals Ltd., a pharmaceutical company, received final approval from the US health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. 

The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.